Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> FLT3

FLT3

FLT3 (FMS-like tyrosine kinase 3) is a cytokine receptor which belongs to the receptor tyrosine kinase class III and plays a role in cell survival, proliferation, and differentiation.

Products for  FLT3

  1. Cat.No. Product Name Information
  2. GC63864 (E/Z)-Zotiraciclib hydrochloride

    (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride

     (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib hydrochloride Chemical Structure
  3. GC39689 3-Hydroxy Midostaurin

    CGP52421

     3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412. 3-Hydroxy Midostaurin Chemical Structure
  4. GC63805 4SC-203 4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs. 4SC-203 Chemical Structure
  5. GC11205 5'-Fluoroindirubinoxime

    5’-FIO, 5′-Fluoroindirubinoxime

     FMS-like receptor tyrosine kinase-3 (FLT3) inhibitor 5'-Fluoroindirubinoxime Chemical Structure
  6. GC18167 AC710

    A potent and selective PDGFR family inhibitor

     AC710 Chemical Structure
  7. GC66451 AKN-028 acetate AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML). AKN-028 acetate Chemical Structure
  8. GC16604 Altiratinib

    DCC-2701

     c-MET/TIE-2/VEGFR inhibitor Altiratinib Chemical Structure
  9. GC14974 AMG 925 FLT3/CDK4 inhibitor,potent and selective AMG 925 Chemical Structure
  10. GC35315 AMG 925 HCl AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. AMG 925 HCl Chemical Structure
  11. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

     A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56) Chemical Structure
  12. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)

    MP470 hydrochloride; HPK 56 hydrochloride

     Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride) Chemical Structure
  13. GC10914 AST 487

    NVP-AST 487

     A multi-kinase inhibitor AST 487 Chemical Structure
  14. GC10638 AT9283 A broad spectrum kinase inhibitor AT9283 Chemical Structure
  15. GC62499 ATH686 ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects. ATH686 Chemical Structure
  16. GC73370 AXL-IN-13 AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 Chemical Structure
  17. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  18. GC19080 BPR1J-097 BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM. BPR1J-097 Chemical Structure
  19. GC35544 BPR1J-097 Hydrochloride BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11?nM. BPR1J-097 Hydrochloride Chemical Structure
  20. GC35545 BPR1K871

    DBPR114

     BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy. BPR1K871 Chemical Structure
  21. GC15779 Cabozantinib (XL184, BMS-907351)

    BMS-907351, Cabozantinib

     Cabozantinib (XL184,BMS-907351) is a novel MET and VEGFR2 inhibitor that simultaneously inhibits metastasis, angiogenesis and tumor growth. Cabozantinib (XL184, BMS-907351) Chemical Structure
  22. GC19092 CCT241736 CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). CCT241736 Chemical Structure
  23. GC73970 CDDD11-8 CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 Chemical Structure
  24. GC35651 Cenisertib

    AS-703569; R-763

     Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib Chemical Structure
  25. GC33064 CG-806 (Luxeptinib)

    CG-806

     CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. CG-806 (Luxeptinib) Chemical Structure
  26. GC15739 CHIR-124 Chk1 inhibitor,novel and potent CHIR-124 Chemical Structure
  27. GC14906 Crenolanib (CP-868596)

    CP-868596;CP 868596;CP868596

     Crenolanib (CP-868596) is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively. Crenolanib (CP-868596) Chemical Structure
  28. GC38412 Crotonoside

    2-Hydroxyadenosine, Isoguanine riboside, Isoguanosine, NSC 12161

     Crotonoside is a FLT3 and HDAC3/6 inhibitor that can be used to study acute myeloid leukemia (AML). Crotonoside Chemical Structure
  29. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

     DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib) Chemical Structure
  30. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  31. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  32. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  33. GC32968 FLT3-IN-1 FLT3-IN-1 Chemical Structure
  34. GC33242 FLT3-IN-1 Succinate FLT3-IN-1 Succinate Chemical Structure
  35. GC63936 FLT3-IN-10 FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML). FLT3-IN-10 Chemical Structure
  36. GC65984 FLT3-IN-16 FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia. FLT3-IN-16 Chemical Structure
  37. GC73149 FLT3-IN-17 FLT3-IN-17 inhibits CYPs and FLT3 mutants activity (IC50s: <0.5 nM for D835Y). FLT3-IN-17 Chemical Structure
  38. GC73449 FLT3-IN-19 FLT3-IN-19 (Comp 50) is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM. FLT3-IN-19 Chemical Structure
  39. GC19158 FLT3-IN-2 FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 uM, detailed information refer to WO 2012158957 A2 and WO 2007013896. FLT3-IN-2 Chemical Structure
  40. GC19772 FLT3-IN-3

    SAN50900

    FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

     FLT3-IN-3 Chemical Structure
  41. GC36055 FLT3-IN-4 FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia. FLT3-IN-4 Chemical Structure
  42. GC36056 FLT3-IN-6 FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM. FLT3-IN-6 Chemical Structure
  43. GC33049 FN-1501 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. FN-1501 Chemical Structure
  44. GC12178 G-749

    G-749

     FLT3 inhibitor G-749 Chemical Structure
  45. GC19482 Gilteritinib

    ASP2215

     Gilteritinib (ASP2215, Xospata) for relapsed and /or refractory AML (R/R AML). Gilteritinib Chemical Structure
  46. GC36135 Gilteritinib hemifumarate

    ASP2215 hemifumarate

     Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. Gilteritinib hemifumarate Chemical Structure
  47. GC63507 HM43239

    HM43239

     HM43239 is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. HM43239 inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. HM43239 inhibits the proliferation and induces the apoptosis of leukemic cells. HM43239 Chemical Structure
  48. GC73012 HPK1-IN-2 dihydrochloride HPK1-IN-2 didrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride Chemical Structure
  49. GC43885 Hypothemycin

    NSC 354462

     A resorcylic acid lactone polyketide Hypothemycin Chemical Structure
  50. GC62500 JAK2-IN-7 JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities. JAK2-IN-7 Chemical Structure
  51. GC62665 JAK2/FLT3-IN-1 TFA JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. JAK2/FLT3-IN-1 TFA Chemical Structure
  52. GC32995 JNJ-47117096 hydrochloride (MELK-T1 hydrochloride)

    MELK-T1 hydrochloride

     JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM. JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) Chemical Structure
  53. GC14592 KW 2449 A multi-kinase inhibitor KW 2449 Chemical Structure
  54. GC17033 Lestaurtinib

    CEP-701; KT-5555

     A potent JAK2 and PRK1 kinase inhibitor Lestaurtinib Chemical Structure
  55. GC17958 Linifanib (ABT-869)

    Linifanib

     Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  56. GC13848 LY2784544

    Gandotinib

     Potent inhibitor of JAK2 LY2784544 Chemical Structure
  57. GC11057 LY2801653

    Merestinib

     A MET kinase inhibitor LY2801653 Chemical Structure
  58. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  59. GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate Chemical Structure
  60. GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate Chemical Structure
  61. GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). Merestinib dihydrochloride Chemical Structure
  62. GC32769 MRX-2843 (UNC2371)

    UNC2371

     MRX-2843 (UNC2371) (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively. MRX-2843 (UNC2371) Chemical Structure
  63. GC68433 OTS447 OTS447 Chemical Structure
  64. GC41329 Pacritinib FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate cytokine signaling and are frequently mutated in cancers, particularly acute myeloid leukemia. Pacritinib Chemical Structure
  65. GC73096 PF15 TFA PF15 TFA is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 TFA Chemical Structure
  66. GC73497 PHI-101 PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 Chemical Structure
  67. GC14396 Ponatinib (AP24534)

    AP 24534

     Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  68. GC65555 PROTAC FLT-3 degrader 1 PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction. PROTAC FLT-3 degrader 1 Chemical Structure
  69. GC17615 Quizartinib (AC220)

    AC220

     Quizartinib (AC220) (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib (AC220) inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib (AC220) can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib (AC220) induces apoptosis. Quizartinib (AC220) Chemical Structure
  70. GC37538 Ripretinib

    DCC-2618

     Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. Ripretinib Chemical Structure
  71. GC73373 RSH-7 RSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively. RSH-7 Chemical Structure
  72. GC12064 SB1317

    TG02, Zotiraciclib

     A multi-kinase inhibitor SB1317 Chemical Structure
  73. GC11455 Silvestrol Silvestrol Chemical Structure
  74. GC19332 Sitravatinib

    MGCD-516

     Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/L. Sitravatinib Chemical Structure
  75. GC33141 SKLB4771 (FLT3-IN-1)

    FLT3-?IN-?1

     SKLB4771 (FLT3-IN-1) is a potent and selective Flt3 inhibitor with an IC50 value of 10 nM. SKLB4771 (FLT3-IN-1) downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue. SKLB4771 (FLT3-IN-1) Chemical Structure
  76. GC17369 Sorafenib

    BAY 43-9006

    Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC50 values of 6 nM and 22 nM, respectively.

     Sorafenib Chemical Structure
  77. GC37664 Sorafenib (D3)

    BAY 43-9006-d3

     An internal standard for the quantification of sorafenib Sorafenib (D3) Chemical Structure
  78. GC37665 Sorafenib (D4)

    Bay 43-9006-d4

     Sorafenib (D4) (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. Sorafenib (D4) Chemical Structure
  79. GC15307 SU5416

    NSC 696819, Semaxinib, Sugen 5416, VEGFR 2 Kinase Inhibitor

     SU5416 is a potent small molecule vascular endothelial growth factor receptor (VEGFR) inhibitor. SU5416 Chemical Structure
  80. GC14582 SU5614 SU5614 is a potent FLT3 inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3. SU5614 Chemical Structure
  81. GC37723 TAK-659 TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL). TAK-659 Chemical Structure
  82. GC15254 Tandutinib (MLN518)

    CT 53518, MLN518

     Tandutinib (MLN518) (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib (MLN518) can be used for acute myelogenous leukemia (AML). Tandutinib (MLN518) has the ability to cross the blood-brain barrier. Tandutinib (MLN518) Chemical Structure
  83. GC12251 Tandutinib (MLN518) HCl FLT3 inhibitor,potent and selective Tandutinib (MLN518) HCl Chemical Structure
  84. GC38853 Tandutinib hydrochloride

    MLN518 hydrochloride; CT53518 hydrochloride

     Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier. Tandutinib hydrochloride Chemical Structure
  85. GC12058 TCS 359

    Fms-like Tyrosine Kinase Inhibitor, TCS 359

     Potent FLT3 inhibitor TCS 359 Chemical Structure
  86. GC10035 TG101209 An inhibitor of JAK2, FLT3, RET, and JAK3 TG101209 Chemical Structure
  87. GC69233 Tuspetinib

    HM43239

    Tuspetinib (HM43239) is a selective FLT3 inhibitor with oral activity, with IC50 values of 1.1 nM (wild-type FLT3), 1.8 nM (FLT3 ITD mutation), and 1.0 nM (FLT3 D835Y mutation). As a reversible type I inhibitor, Tuspetinib directly inhibits the kinase activity of FLT3 and regulates p-STAT5, p-ERK SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation of leukemia cells and induces apoptosis.

     Tuspetinib Chemical Structure
  88. GC15556 UNC2025 orally bioavailable dual MER/FLT3 inhibitor UNC2025 Chemical Structure
  89. GC37857 UNC2025 hydrochloride UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki?= 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia. UNC2025 hydrochloride Chemical Structure
  90. GC62516 UNC5293 UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research. UNC5293 Chemical Structure
  91. GC73501 Wu-5 Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis. Wu-5 Chemical Structure
  92. GC62112 Zotiraciclib Zotiraciclib Chemical Structure

91 Item(s)

per page

Set Descending Direction